证券简称：国新健康 证券代码：000503 编号：2025-47 1、国新健康保障服务集团股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日披露了《关于控股股东及其一致行动人增持股份计划的公告》（公告编号： 2025-16），公司控股股东中海恒实业发展有限公司（以下简称"中海恒"）及 其一致行动人国新发展投资管理有限公司（以下简称"国新发展"）计划在自公 告之日起 6 个月内，通过集中竞价等深圳证券交易所允许的方式增持公司股份， 拟增持金额不低于人民币 1 亿元，不超过人民币 2 亿元。 2、截至本公告披露日，前述增持计划时间已过半，增持主体根据自身的统 筹安排，暂未增持公司股份，将在后续的增持计划期间严格按照法律法规的相关 要求，及时履行信息披露告知义务。 近日，公司接到控股股东中海恒及其一致行动人国新发展《关于股份增持计 划时间过半的实施情况告知函》，现将相关情况公告如下： 国新健康保障服务集团股份有限公司 关于控股股东及其一致行动人增持股份计划实施进展暨增持时 间过半的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： （二） ...

Core Insights - GuoXin Health launched the "Tianshu·SanYi" large model and "Lingxi" intelligent platform, focusing on the integration of healthcare, medical insurance, and pharmaceuticals, marking a new phase in the digital transformation of the healthcare industry [1] - The initiative is driven by the State Council's "Artificial Intelligence+" action plan, leveraging over 20 years of industry experience and a service network covering more than 200 medical insurance clients, 800 hospitals, and over 20 drug regulatory agencies [1] Group 1 - The "Tianshu·SanYi" model addresses industry bottlenecks through four core capabilities: knowledge system foundation, professional knowledge graph empowerment, business insights navigation, and A2A global orchestration [2] - The knowledge system is built on high-quality datasets accumulated over two decades, establishing a "SanYi brain" knowledge hub that enhances the model's cognitive abilities [2] - The professional knowledge graph includes 3.55 million entity nodes and 150 million triples, enabling intelligent mapping of treatment norms, medication rules, and medical insurance policies [2] Group 2 - The model features four distinct characteristics: a growing model that supports real-time data updates and decision-making, a more accurate model with a hallucination rate below 3%, a customer-centric model that incorporates specialized knowledge, and a collaborative model that enhances operational efficiency [3] - The "Lingxi" platform focuses on integrating healthcare, medical insurance, and pharmaceutical services, creating a matrix of intelligent applications to reshape business processes and drive industry innovation [3]

Group 1 - The 2024 Annual General Meeting of the company was held on June 26, 2025, in Beijing, combining on-site and online voting [4][3] - A total of 412 shareholders participated in the voting, representing 291,022,880 shares, which accounts for 29.6565% of the total voting shares [5] - The meeting was convened by the board of directors and chaired by Chairman Li Yonghua [4] Group 2 - All proposals presented at the meeting were approved without any rejections [2] - The voting results for the 2024 Annual Report showed 99.7999% approval from the total voting shares [8] - The proposal for the 2024 financial settlement report received 99.5719% approval from the total voting shares [14] Group 3 - The company plans to repurchase and cancel 1,951,260 shares of restricted stock due to unmet performance targets for 2024 [35] - Following the repurchase, the total share capital will decrease from 981,312,532 shares to 979,361,272 shares [36] - Creditors have the right to claim their debts within 30 days of receiving notice of the share repurchase [37]

Core Viewpoint - The company has approved the repurchase and cancellation of 1,951,260 restricted shares as part of its first phase of the restricted stock incentive plan, which will lead to a reduction in registered capital [1][2]. Group 1 - The company held its annual general meeting on June 26, 2025, where the proposal for the repurchase and cancellation of remaining restricted shares was approved [1]. - The repurchase will be conducted at the lower of the grant price or the market price at the time of repurchase, as stipulated in the incentive plan [1]. - The total number of shares to be repurchased and canceled is 1,951,260, which will affect the company's total share capital [1]. Group 2 - The repurchase and cancellation of shares will result in a decrease in the company's registered capital, and creditors have the right to claim their debts within specified timeframes [2]. - Creditors can submit their claims via mail, fax, or email, and must provide valid proof of their claims [2]. - The company will follow legal procedures for the cancellation of the repurchased shares [2].

证券简称：国新健康 证券代码：000503 编号：2025-45 国新健康保障服务集团股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1、本次股东大会未出现否决提案的情形。 一、会议的召开情况 国新健康保障服务集团股份有限公司（以下简称"公司"）2024 年度股东 大会于 2025 年 6 月 26 日在北京市东城区沙滩后街 22 号院 2 号楼、3 号楼公司 会议室以现场和网络投票相结合的方式召开。本次会议由公司董事会召集，由公 司董事长李永华先生主持。 会议通知等相关文件已于 2025 年 6 月 6 日、2025 年 6 月 20 日在《中国证 券报》《上海证券报》《证券时报》以及巨潮资讯网（网址：www.cninfo.com.cn） 披露。会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章 程》的规定。 二、会议的出席情况 股东出席的总体情况： 参与投票的股东 412 人，代表股份 291,022,880 股，占公司有表决权股份总 数的 29.6565％。 公司董事会、监事会成员、高 ...

国新健康保障服务集团股份有限公司 证券简称：国新健康 证券代码：000503 编号：2025-46 关于回购注销部分限制性股票暨通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）于 2025 年 6 月 5 日召开的第十一届董事会第二次会议和第十二届监事会第二次会议，以及 2025 年 6 月 26 日召开的 2024 年度股东大会，审议通过了《关于限制性股票激励计划 （第一期）回购注销剩余全部限制性股票的议案》。 根据公司《限制性股票激励计划（第一期）（草案修订稿）》的规定，鉴于 2024 年公司业绩考核未达标，公司本次激励计划首次授予第三个解除限售期解 除限售条件未成就，公司须对首次授予激励对象第三个解除限售期对应的限制性 股票按照授予价格与回购时市价孰低值回购处理，需回购注销剩余限制性股票共 1,951,260 股。 公司本次回购注销的限制性股票共 1,951,260 股，预计公司总股本将由 981,312,532 股变更为 979,361,272 股，注册资本也将由 981,312,5 ...

北京观韬律师事务所 关于国新健康保障服务集团股份有限公司 2024 年度股东大会 法律意见书 观意字 2025BJ001477 号 致：国新健康保障服务集团股份有限公司 北京观韬律师事务所（以下简称"本所"）受国新健康保障服务集团股份有限公 司（以下简称"公司"）委托，指派本所律师出席公司 2024 年度股东大会（以下简 称"本次股东大会"或"本次会议"），并依据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》《上市公司股东会规则》（以下简 称"《规则》"）以及公司现行有效的《公司章程》的有关规定，对公司于 2025 年 6 月 26 日召开的本次股东大会进行见证，出具本法律意见书。 本所律师同意将本法律意见书作为公司本次股东大会公告材料，随其他需公 告的信息一起向公众披露。本法律意见书仅供公司为本次股东大会之目的而使用， 不得用作任何其他目的。本所律师保证本法律意见书所发表的结论合法、准确，不 存在虚假记载、严重误导性陈述及重大遗漏，否则愿意承担相应的法律责任。 在本法律意见书中，本所律师仅对本次会议召集和召开程序是否符合法律、行 政法规、《规则》和《公司章程》的规定、出席本次 ...

Market Performance - As of June 26, the DRG/DIP concept index rose by 1.97%, ranking fifth among concept sectors, with 16 stocks increasing in value [1] - Notable gainers included Kechuang Information, which hit a 20% limit up, and Huayu Software, Guoxin Health, and Digital Certification, which rose by 4.75%, 3.69%, and 3.50% respectively [1] - The sectors with the highest and lowest daily performance included the Military Equipment Restructuring concept at +8.73% and the Photolithography Machine concept at -1.48% [1] Capital Flow - The DRG/DIP concept sector saw a net inflow of 412 million yuan, with 14 stocks receiving net inflows, and 5 stocks attracting over 30 million yuan each [1] - Kechuang Information led the net inflow with 205 million yuan, followed by Guoxin Health, Huayu Software, and Digital Certification with net inflows of 69.67 million yuan, 64.82 million yuan, and 47.87 million yuan respectively [1] - The top three stocks by net inflow ratio were Kechuang Information at 20.10%, Guoxin Health at 13.05%, and Huayu Software at 11.15% [2]

Group 1 - The DRG/DIP sector is experiencing a rise, with stocks such as Saili Medical (603716) hitting the daily limit up [1] - Other companies like Chuangying Huikang (300451), Dian Diagnostics (300244), Sichuang Medical (300078), Guoxin Health (000503), and Jiuyuan Yinhai (002777) are also seeing significant increases [1] - There is an influx of dark pool funds into these stocks, indicating strong investor interest [1]

国证券报》 《证券时报》及巨潮资讯网（网址：www.cninfo.com.cn） 披露的《关于使用暂时闲置的募集资金进行现金管理的公告》（公告编号： 为提高公司募集资金使用效率，公司于 2025 年 6 月 5 日召开第十二届董事 会第二次会议和第十二届监事会第二次会议，审议通过了《关于增加使用暂时闲 置募集资金进行现金管理的额度的议案》，同意公司（含国新健康保障服务有限 公司、北京海协智康科技发展有限公司、国新益康数据（北京）有限公司三家子 公司）使用闲置募集资金进行现金管理的总额度由 4.5 亿元（含本数）增加至 5.5 亿元（含本数），使用期限自本次董事会审议通过之日起至 2026 年 1 月 28 日止， 并由董事会授权公司总经理在上述额度及决议有效期内行使投资决策权，在前述 额度及期限范围内，资金可以循环滚动使用。详见公司于 2025 年 6 月 6 日在《中 《上海证券报》 证券简称：国新健康 证券代码：000503 编号：2025-43 国新健康保障服务集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限 ...